The American Association for Cancer Research (AACR) is gearing up for its 117th Annual Meeting, set to take place from April 17-22, 2026, at the San Diego Convention Center. This highly anticipated event promises to be a hub of groundbreaking discoveries and advancements in cancer research, attracting over 22,000 researchers, physicians, and advocates from around the globe.
This year's meeting will showcase a diverse range of topics, with a particular focus on clinical trials and their impact on cancer treatment. One of the key presentations that caught my attention is the investigation into a novel KRAS(ON) inhibitor, Zoldonrasib, which demonstrated remarkable efficacy and long-lasting responses in patients with advanced G12D-mutated lung cancer. Byoung Chul Cho, MD, PhD, from Yonsei Cancer Center, Yonsei University College of Medicine, will be presenting this groundbreaking research.
Another presentation that piques my interest is the exploration of the next-generation KRAS G12C inhibitor, Elisrasib. Jonathan W. Riess, MD, from the UC Davis Comprehensive Cancer Center, will discuss its promising response rates in patients with advanced lung cancer. This development could potentially revolutionize the treatment landscape for this challenging disease.
Furthermore, the meeting will address the unmet needs in advanced platinum-resistant ovarian cancer. Tao Zhu, MD, from Zhejiang Cancer Hospital, will present a new antibody-drug conjugate that has shown clinical benefit in this difficult-to-treat population. These advancements highlight the ongoing efforts to improve outcomes for patients with cancer, particularly those with limited treatment options.
The AACR Annual Meeting is not just about scientific presentations; it's also a platform for collaboration and knowledge exchange. Researchers and clinicians can engage in discussions, share insights, and forge new partnerships that will accelerate progress in cancer research. The event's impact extends beyond the meeting itself, as it contributes to the development of innovative therapies and improved patient care.
In my opinion, the AACR Annual Meeting 2026 is a testament to the relentless pursuit of scientific excellence in cancer research. The presentations mentioned above are just a glimpse into the wealth of knowledge that will be shared during the event. I am particularly excited to see how these discoveries will shape the future of cancer treatment and patient care, potentially leading to more effective therapies and improved survival outcomes.
